Effects of XXXX on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia.

@entity1 @entity753 @entity3413 @entity301 @entity9478 @entity755 @entity1675 @entity9477 @entity165
The effect of 24 weeks of treatment with @entity3413 , a new HMG coenzyme A reductase inhibitor (dosages of 20 and 40 mg day-1) on serum lipid, lipoprotein and @entity1675 and B concentrations as well as safety parameters and subjective side effects were studied in 11 @entity1 with familial ( @entity753 ) and 10 @entity1 with polygenic hypercholesterolaemia (P-HC). The effects on plasma lipoprotein and apolipoprotein concentrations had already been achieved after four weeks in both groups and then remained during the study. In @entity753 , mean fasting plasma total @entity165 concentration decreased from 10.51 to 6.71 mmol l-1 (36%), and in P-HC from 6.55 to 4.54 mmol l-1 (31%) at 24 weeks (P less than 0.001). Mean plasma low density lipoprotein (LDL) @entity165 concentrations also decreased, in @entity753 from 8.87 to 5.05 mmol l-1 (43%) and in P-HC from 4.97 to 3.12 mmol l-1 (37%) at 24 weeks (P less than 0.001). Furthermore, @entity755 concentrations decreased significantly from 2.21 to 1.57 g l-1 (29%) (less than 0.001) in @entity753 and from 1.53 to 1.09 g l-1 (29%) (P less than 0.01) in P-HC. Plasma high density lipoprotein (HDL) @entity165 increased in both @entity753 and P-HC during treatment. Increases were seen in both the subfractions @entity9477 and @entity9478 . @entity3413 was well tolerated. No serious clinical or laboratory adverse effects were observed. It is concluded that 24 weeks of treatment with @entity3413 in doses up to 40 mg day-1 effectively reduces plasma total and LDL @entity165 concentrations without causing subjective or significant objective side effects. Thus, @entity3413 may be of great interest in future studies for prevention of @entity301 due to hypercholesterolaemia.
